Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methaemoglobin (MetHb) is a form of hemoglobin with iron in the ferric (Fe³⁺) state, unable to bind or transport oxygen. Elevated levels cause methemoglobinemia, impairing tissue oxygenation. It is normally kept at low levels by the enzyme cytochrome b5-methemoglobin reductase. Methemoglobinemia can be inherited or acquired through exposure to certain drugs or chemicals.
Methylene blue accelerates reduction of methaemoglobin back to hemoglobin.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methaemoglobin (MetHb).